Daniel Pollyea, MD, MS, explains the risk factors for acute myeloid leukemia, the importance of biomarker testing, and the challenges that prevent every patient from being tested.
Acute Myeloid Leukemia: Advances in Initial Therapy
A hematologist details the frontline treatment options and goals in acute myeloid leukemia and describes venetoclax.
Dr. Pollyea breaks down data from the recent VIALE-A phase III clinical trial.
An expert describes the considerations in choosing to treat acute myeloid leukemia patients with venetoclax.
Daniel Pollyea, MD, MS, discusses the unmet needs and future management strategies of acute myeloid leukemia.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma
3
Lurbinectedin Contributes to Maintenance of Response in ES-SCLC
4
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
5
